Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...

Earlier this week, PTC Therapeutics reported positive 24‑month interim data from the PIVOT-HD extension study, showing dose-dependent slowing of Huntington’s disease progression with votoplam and a ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics ...

PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington’s disease, highlighting what ...

PTC Therapeutics Inc. PTCT shares are tumbling on Wednesday, after the company reported topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study. According to a ...

Allows users to ask questions in natural language to quickly find answers through an embedded chat interface BOSTON, ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...

PTC announced the acquisition of the cloud-native computer-aided Manufacturing (CAM) solution, CloudMilling. Terms of the transaction were not disclosed. The UK-based father and son team, which had ...

“We”—old timers, old heads, just plain old—sometimes refer to ourselves as “fossils,” but we’re not really. Fossils, as far as “we” know, can’t think, change positions, make jokes, whine, or delude ...